Track Aclarion Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Aclarion Inc. Common Stock ACON · Stock Open Aclarion Inc. Common Stock in new tab

1.56 USD
EPS
-5.01
P/B
0.30
ROE
-74.07
Beta
1.21
Target Price
7.63 USD
Loading chart...
Key Metrics
Earnings dateMarch 3, 2027
EPS-5.01
Book Value5.14
Price to Book0.30
Debt/Equity47.32
% Insiders23.976%
Growth
Revenue Growth0.78%
Estimates
Forward P/E-0.29
Forward EPS-5.47
Target Mean Price7.63

DCF valuation

Model fair value for Aclarion Inc. Common Stock (ACON)
Result
Sign in to run the valuation for ACON.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
2 analysts · consensus None · mean target 7.63 USD (low 7.50, high 7.75) · as of 14 Nov 2026
Low 7.50
Mean 7.63
High 7.75
Price 1.56
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Aclarion Inc. Common Stock Logo Aclarion Inc. Common Stock Analysis (ACON)

United States Information Technology Official Website Stock

Is Aclarion Inc. Common Stock a good investment? Aclarion Inc. Common Stock (ACON) is currently trading at 1.56 USD. Market analysts have a consensus price target of 7.63 USD. This suggests a potential upside from current levels.

Earnings Schedule: Aclarion Inc. Common Stock is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is -5.47.

Investor FAQ

Does Aclarion Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Aclarion Inc. Common Stock?

Aclarion Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -5.01.

Company Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Exchange Ticker
NMS (United States) ACON
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Jan. 4, 2024 1:16
Jan. 29, 2025 Needs review
March 28, 2025 1:27
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion